Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Systemic administration of an alpha-7 nicotinic acetylcholine agonist reverses neuropathic pain in male Sprague Dawley rats.

Loram LC, Taylor FR, Strand KA, Maier SF, Speake JD, Jordan KG, James JW, Wene SP, Pritchard RC, Green H, Van Dyke K, Mazarov A, Letchworth SR, Watkins LR.

J Pain. 2012 Dec;13(12):1162-71. doi: 10.1016/j.jpain.2012.08.009.

2.
3.

A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.

Gierse J, Thorarensen A, Beltey K, Bradshaw-Pierce E, Cortes-Burgos L, Hall T, Johnston A, Murphy M, Nemirovskiy O, Ogawa S, Pegg L, Pelc M, Prinsen M, Schnute M, Wendling J, Wene S, Weinberg R, Wittwer A, Zweifel B, Masferrer J.

J Pharmacol Exp Ther. 2010 Jul;334(1):310-7. doi: 10.1124/jpet.110.165845. Epub 2010 Apr 14.

PMID:
20392816
4.

Utilizing a novel tandem oral dosing strategy to enhance exposure of low-solubility drug candidates in a preclinical setting.

Chiang PC, South SA, Foster KA, Daniels JS, Wene SP, Albin LA, Thompson DC.

J Pharm Sci. 2010 Jul;99(7):3132-40. doi: 10.1002/jps.22092.

PMID:
20229600
5.

Aqueous versus non-aqueous salt delivery strategies to enhance oral bioavailability of a mitogen-activated protein kinase-activated protein kinase (MK-2) inhibitor in rats.

Chiang PC, South SA, Daniels JS, Anderson DR, Wene SP, Albin LA, Mourey RJ, Selbo JG.

J Pharm Sci. 2009 Jan;98(1):248-56. doi: 10.1002/jps.21425.

PMID:
18449936

Supplemental Content

Support Center